SAFETY OF SELECTIVE SEROTONIN REUPTAKE INHIBITOR (SSRI) USE IN ELDERLY PEOPLE: AN INTEGRATIVE REVIEW

Authors

  • Daniel Kennedy Sarmento de Sousa Centro Universitário Santa Maria - UNIFSM
  • José Guilherme Ferreira Marques Galvão Centro Universitário Santa Maria - UNIFSM
  • Diego Igor Alves Fernandes de Araújo Universidade Federal da Paraíba https://orcid.org/0000-0002-8032-6240
  • Francisca Sabrina Vieira Lins Centro Universitário Santa Maria - UNIFSM
  • Rafaela de Oliveira N´´obrega Centro Universitário Santa Maria - UNIFSM

DOI:

https://doi.org/10.61164/fatdw498

Keywords:

Selective Serotonin Reuptake Inhibitors, Elderly, Patient Safety, Adverse Effects

Abstract

Population aging increases the prevalence of depressive disorders in older adults, requiring attention to treatment safety. Selective Serotonin Reuptake Inhibitors (SSRIs) are widely used in this age group, but physiological changes, comorbidities, and polypharmacy elevate the risk of adverse events and drug interactions. Evaluating the safety of SSRI use in older adults is, therefore, essential. This study aims to describe, through an integrative literature review, the available scientific evidence on the safety of SSRI use in elderly patients, focusing on adverse events, drug interactions, and specific precautions.This is an integrative literature review with a systematic search in the MEDLINE/PubMed, SciELO, and LILACS databases. Descriptors will be selected from the Health Sciences Descriptors (DeCS) and Medical Subject Headings (MeSH): "Selective Serotonin Reuptake Inhibitors," "Elderly," "Safety," "Adverse Effects," and "Drug Interactions," combined with the Boolean operators AND and OR. The inclusion criteria will cover studies evaluating SSRI safety in individuals aged 60 or older, published between 2015 and 2025, in Portuguese and English. Studies that do not specifically address the elderly population or safety aspects, animal studies, and articles without full text will be excluded. The data analysis will be qualitative, aiming to organize and interpret the information obtained to support the discussion of the issue.It is expected to achieve a comprehensive and updated synthesis on the safety profile of SSRIs in older adults, identifying the main adverse events, relevant drug interactions, precautions for vulnerable subgroups, and strategies to optimize therapeutic safety. The findings aim to contribute to evidence-based clinical practice, assisting healthcare professionals in decision-making regarding SSRI prescriptions for older adults, and foster academic discussions on the topic.

Downloads

Download data is not yet available.

References

BEHLKE, L. M.; LENZE, E. J.; CARNEY, R. M. The cardiovascular effects of newer antidepressants in older adults and those with or at high risk for cardiovascular diseases. CNS Drugs, v. 34, n. 11, p. 1133-1147, 2020. DOI: https://doi.org/10.1007/s40263-020-00763-z

BLAZER, D. G. Depression in late life: review and commentary. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, v. 58, n. 3, p. 249-265, 2003. DOI: https://doi.org/10.1093/gerona/58.3.M249

CHU, A.; WADHWA, R. Inibidores seletivos de recaptação de serotonina. In: StatPearls. Treasure Island (FL): StatPearls Publishing, 2025. PMID: 32119293.

COUPLAND, C. et al. Antidepressant use and risk of adverse outcomes in people aged 20-64 years: cohort study using a primary care database. BMC Medicine, v. 16, n. 1, p. 36, 2018. DOI: https://doi.org/10.1186/s12916-018-1022-x

FOONG, A. L. et al. Demystifying serotonin syndrome (or serotonin toxicity). Canadian Family Physician, v. 64, n. 10, p. 720-727, 2018.

GEBARA, M. A. et al. Cause or effect? Selective serotonin reuptake inhibitors and falls in older adults: a systematic review. American Journal of Geriatric Psychiatry, v. 23, n. 10, p. 1016-1028, 2015. DOI: https://doi.org/10.1016/j.jagp.2014.11.004

MALLERY, L. et al. Systematic review and meta-analysis of second-generation antidepressants for the treatment of older adults with depression: questionable benefit and considerations for frailty. BMC Geriatrics, v. 19, n. 1, p. 306, 2019. DOI: https://doi.org/10.1186/s12877-019-1327-4

NÓBREGA, I. et al. Fatores associados à depressão em idosos institucionalizados: revisão integrativa. Saúde em Debate, v. 39, n. 3, p. 536-550, 2015. DOI: https://doi.org/10.1590/0103-110420151050002020

ORGANIZAÇÃO PAN-AMERICANA DA SAÚDE (OPAS). Depressão. Disponível em: https://www.paho.org/pt/topicos/depressao. Acesso em: 26 mar. 2025.

SAVIOLI, F. Inibidores da recaptação de serotonina associados ao risco de sangramento em idosos submetidos à cirurgia ortopédica. Einstein (São Paulo), v. 17, n. 4, eED5214, 2019. Disponível em: https://doi.org/10.31744/einstein_journal/2019ED5214. Acesso em: 26 mar. 2025. DOI: https://doi.org/10.31744/einstein_journal/2019ED5214

SEPPALA, L. J. et al. Fall-risk-increasing drugs: a systematic review and meta-analysis: II. Psychotropics. Journal of the American Medical Directors Association, v. 19, n. 4, p. 371.e11-371.e17, 2018. DOI: https://doi.org/10.1016/j.jamda.2017.12.098

SOUZA, M. T.; SILVA, M. D.; CARVALHO, R. Revisão integrativa: o que é e como fazer. Einstein (São Paulo), v. 8, n. 1, p. 102-106, 2010. DOI: https://doi.org/10.1590/s1679-45082010rw1134

TAYLOR, D.; PATON, C.; KAPUR, S. The Maudsley prescribing guidelines in psychiatry. 12. ed. Wiley-Blackwell, 2014.

WAADE, R. B. et al. Serum concentrations of antidepressants in the elderly. Therapeutic Drug Monitoring, v. 42, n. 1, p. 32-37, 2020.

Published

2025-12-05

How to Cite

SAFETY OF SELECTIVE SEROTONIN REUPTAKE INHIBITOR (SSRI) USE IN ELDERLY PEOPLE: AN INTEGRATIVE REVIEW. (2025). Revista Multidisciplinar Do Nordeste Mineiro, 21(01), 1-13. https://doi.org/10.61164/fatdw498